1-3 of 3
Tomas Gucky
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Anti-leukemic efficacy of a novel inhibitor for KMT2A-r/FLT3-driven AML via multi-kinase targeting and synergy with menin inhibition

Free
Nikola Niederlova, Pavla Koralkova, Pavla Chaloupkova, Lubos Janotka, Iveta Hradilova, Jan Gursky, Barbora Soucova, Helena Urbankova, Eva Reznickova, Tomas Gucky, Denisa Myslivcova, Monika Belickova, Hana Votavova, Vladimir Krystof, Vladimir Divoky
Journal: Blood
Blood (2025) 146 (Supplement 1): 5059.
https://doi.org/10.1182/blood-2025-5059
Published: 2025
Journal Articles

Targeting of SFK and G6PD Contributes to Anti-Leukemic Activity of Novel FLT3 Trisubstituted Purine Inhibitors: Effective Therapeutic Approach for AML with FLT3 Mutations

Free
Pavla Koralkova, Nikola Niederlova, Iveta Hradilova, Jan Gursky, Barbora Cudova, Helena Urbankova, Eva Reznickova, Tomas Gucky, Denisa Myslivcova, Monika Belickova, Vladimir Krystof, Vladimir Divoky
Journal: Blood
Blood (2022) 140 (Supplement 1): 8823–8824.
https://doi.org/10.1182/blood-2022-165022
Published: 2022
Journal Articles

A Novel Dual Class III/Src Family Tyrosine Kinase Inhibitor Is Highly Active Against FLT3-ITD Leukemia Cells In Vivo

Free
Tereza Radosova Muchova, Eva Reznickova, Zuzana Somikova, Tomas Gucky, Miroslav Strnad, DSc, Vladimir Krystof, PhD, Vladimir Divoky, PhD
Journal: Blood
Blood (2016) 128 (22): 1569.
https://doi.org/10.1182/blood.V128.22.1569.1569
Published: 2016